State Street Corp Amends Travere Therapeutics Stake Filing
Ticker: TVTX · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotech
TL;DR
**State Street Corp still holds Travere Therapeutics stock, showing continued institutional backing.**
AI Summary
State Street Corp, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Travere Therapeutics, Inc. common stock as of December 31, 2023. This filing is an amendment, meaning State Street Corp previously reported its stake and is updating that information. For investors, this shows continued institutional interest in Travere Therapeutics, Inc., which can be a positive signal of confidence in the company's future prospects.
Why It Matters
This filing confirms State Street Corp's ongoing institutional investment in Travere Therapeutics, Inc., signaling continued confidence from a major financial player.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate significant risk.
Analyst Insight
Investors should note that a major institution like State Street Corp continues to hold shares in Travere Therapeutics, Inc. This suggests a baseline level of institutional confidence, but further investigation into the exact percentage of ownership and any changes from previous filings would provide more actionable insight.
Key Players & Entities
- State Street Corp (company) — the entity filing the SC 13G/A
- Travere Therapeutics, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the date the SC 13G/A was filed
FAQ
What type of SEC filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING' sections.
Who is the reporting person in this filing?
The reporting person, or the entity that filed this document, is STATE STREET CORP, as indicated under the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: STATE STREET CORP' section.
What is the subject company whose securities are being reported?
The subject company, or the issuer, is Travere Therapeutics, Inc., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc.' and 'NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 89422G107 (CUSIP NUMBER)'.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified in the '12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)' section.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed pursuant to Rule 13D-1 (B), as indicated by the 'CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B)' section.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Travere Therapeutics, Inc. (TVTX).